What we do Valiant Laboratories Ltd manufactures Active Pharmaceutical Ingredient (API) with a focus on Paracetamol for pain relief and fever treatment, serving pharmaceutical clients globally. |
Founded in 1,980 |
Market share Key player with 9,000 MTPA capacity in Paracetamol APIs in India. |
Problem solved Providing essential pain relief and fever medication APIs with high quality and compliance to global pharmacopeia standards. |
Top clients or who we serve Pharmaceutical companies requiring APIs, primarily B2B in India and limited exports. |
Key management Santosh Vora (Managing Director), Paresh Shah (Executive Director & CFO). |
Our journey and innovations Founded in 1980 as partnership, converted to public company in 2021, listed in 2023; expanded manufacturing capacity and established R&D center. |
Where we operate Mainly India with minimal international sales. Manufacturing and R&D at Maharashtra. |
Top products or what we offer Paracetamol APIs across IP/BP/EP/USP grades; specialty chemicals; in-house R&D driven quality enhancements. |
Top brands No specific brands; flagship product is Paracetamol API with regulatory approval. |
Raw materials needed Raw materials for Paracetamol synthesis, including chemical intermediates sourced locally and internationally. |
Raw materials supplier Various chemical suppliers; specifics not disclosed. |
Recurring vs cyclical contribution Revenue primarily recurring from bulk API contracts with pharmaceutical manufacturers. |
Our industry position Established mid-sized API manufacturer with niche in Paracetamol and specialized chemicals. |
Financial highlights FY 2024-25 revenue Rs.133.38 crore, net loss Rs.2.2 crore, revenue down 26.75% YoY due to market conditions. |
Geographical revenue split Approximately 99.5% revenue from India, less than 1% from international markets. |
Order book - |
Whats driving growth Capacity expansion, regulatory approvals, market demand for quality Paracetamol APIs, and IPO fund utilization. |
Our future plans Enhance manufacturing capacity from 750 to 900 MT/month, expand specialty chemical offerings, strengthen financial stability via rights issue. |
Our green promise Implementing zero liquid discharge, air emission control, energy efficiency, and sustainability initiatives at manufacturing plant. |
Our people and values Seven directors with experienced leadership, focus on safety and compliance, employee health and training emphasized. |
Key challenges ahead Market competition, regulatory compliance, financial turnaround, raw material price volatility. |
Interesting facts One of the few specialized Paracetamol API manufacturers with an in-house R&D and zero liquid discharge facility. |
Risks and strategy Mitigating operational and financial risks through capacity expansion, rights issue capital raise, and stringent quality controls. |
